Lunai Bioworks partners with BrainStorm for neurology drug discovery May 28, 2026 09:16AM
Federal judge grants Lunai expedited discovery in naked short selling case May 22, 2026 09:15AM
LNAI stockholders approve reverse stock split proposal May 13, 2026 04:53PM
Lunai Bioworks subsidiary lands defense contract for AI threat platform Apr 7, 2026 09:09AM
Lunai Bioworks acquires brain delivery tech in $20M deal Mar 26, 2026 08:51AM


Mar 19, 2026 09:59AM Lunai Bioworks forms chemical defense consortium targeting federal programs
Feb 9, 2026 11:15AM Lunai Bioworks outlines three revenue engines in shareholder letter
Jan 27, 2026 10:38AM Lunai Bioworks launches AI safeguard to prevent chemical weapon designs
Jan 26, 2026 09:31AM Lunai Bioworks launches alcohol use disorder drug discovery program
Dec 9, 2025 07:45AM Lunai Bioworks identifies three Parkinson's disease subtypes
Dec 3, 2025 06:12AM Lunai Bioworks enters $11.7 million at-the-market equity offering agreement
Nov 25, 2025 07:45AM Lunai Bioworks secures licensing deal after cancer therapy breakthrough
Nov 5, 2025 09:23AM Lunai Bioworks reports tumor regression in preclinical pancreatic cancer study
Oct 30, 2025 09:33AM Lunai Bioworks develops AI platform for neurotoxic compound detection
Oct 30, 2025 09:32AM Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds
Oct 16, 2025 09:16AM Lunai Bioworks regains compliance with NASDAQ minimum bid price rule
Oct 16, 2025 09:15AM Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement
Oct 6, 2025 09:17AM Lunai Bioworks launches Alzheimer's disease program using AI platform
Oct 6, 2025 09:15AM Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline
Sep 30, 2025 09:15AM Lunai Bioworks completes rebrand and 10:1 reverse stock split
Sep 30, 2025 09:15AM Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense